|
|
 Previous Article | Table of Contents | Next Article 
Clinical importance of CD7 expression in acute myelocytic leukemia. The
Japan Cooperative Group of Leukemia/Lymphoma [see comments]
K Kita, H Miwa, K Nakase, K Kawakami, T Kobayashi, S Shirakawa, I Tanaka, C Ohta, H Tsutani and S Oguma
Second Department of Internal Medicine, Mie University School of Medicine,
Tsu, Japan.
Forty patients (9 females and 31 males; mean age 41.9 years) with CD7+
acute myelocytic leukemia (AML) were investigated; they were classified
into the following subgroups according to French-American-British
classification: 15 M1, 18 M2, 3 M4, and 4 M5. Leukemic cells from all the
patients were negative for T-cell-specific antigens, surface CD3, and
T-cell-receptor molecules. The sex and age distributions were different
from those of CD7- AML patients (P < .01). Hepatomegaly and central
nervous system involvement were also frequent in the CD7+ AML patients. The
phenotype of and responsiveness to hematopoietic growth factors by the
leukemic cells showed their immaturity, as evidenced by frequent expression
of CD34, HLA-DR, and TdT, and the greatest growth response to
interleukin-3. No particular karyotypic abnormality was shown. One hundred
eighty AML patients were treated with a therapeutic regimen routinely used
for AML. The CD7+ AML patients showed a significantly lower response than
CD7- AML patients (P < .01), and had a poorer prognosis (P < .01).
CD7+ AML patients with M1 or M5b had unfavorable responses to the
therapeutic regimen in comparison with patients with M2, M4, or M5a. In
addition, 3 of 4 CD7+ CD2+ AML patients, who did not respond to the
therapy, were induced into complete remission with an acute lymphoblastic
leukemia therapy. The results presented here indicate the diagnostic
importance of CD7 positivity in AML, suggesting that the cellular and
clinical characteristics of CD7+ AML are sufficient for it to be recognized
as a distinct category of AML.
Volume 81,
Issue 9,
pp. 2399-2405,
05/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L.-I. Lin, C.-Y. Chen, D.-T. Lin, W. Tsay, J.-L. Tang, Y.-C. Yeh, H.-L. Shen, F.-H. Su, M. Yao, S.-Y. Huang, et al.
Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells
Clin. Cancer Res.,
February 15, 2005;
11(4):
1372 - 1379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Legrand, J.-Y. Perrot, M. Baudard, A. Cordier, R. Lautier, G. Simonin, R. Zittoun, N. Casadevall, and J.-P. Marie
The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score
Blood,
August 1, 2000;
96(3):
870 - 877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Orfao, G. Schmitz, B. Brando, A. Ruiz-Arguelles, G. Basso, R. Braylan, G. Rothe, F. Lacombe, F. Lanza, S. Papa, et al.
Clinically Useful Information Provided by the Flow Cytometric Immunophenotyping of Hematological Malignancies: Current Status and Future Directions
Clin. Chem.,
October 1, 1999;
45(10):
1708 - 1717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
